Executive Summary
The four regulatory filings from India's MCA compliance and enforcement stream reveal a concentrated pattern of SEBI LODR non-compliance, primarily around board composition and independent director appointments, with fines ranging from ₹47,200 to ₹5,45,160.
Notably, three out of four companies (Medico Remedies, Coal India, and Reliable Data Services) received penalties for governance lapses, while Novelix Pharmaceuticals' filing is a neutral disclosure related to warrant conversion. Period-over-period comparisons show that Coal India's fine (₹5,45,160) is 11.5x larger than Reliable Data Services' (₹47,200), highlighting a materiality gap between a PSU giant and a smaller firm. Insider activity is absent across all filings, but forward-looking statements from Coal India and Reliable Data Services indicate waiver requests, suggesting a pattern of companies contesting penalties. The most critical development is Coal India's non-compliance with multiple board composition regulations (17(1), 18(1), 19(1), 19(2)), which, given its PSU status and market cap, raises governance red flags for state-owned enterprises. The portfolio-level theme is a systemic governance weakness in board independence, with 75% of filings involving director appointment failures, creating a catalyst for stricter MCA enforcement.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior India MCA Corporate Compliance Enforcement digest from June 02, 2026.
Investment Signals (8)
- Medico Remedies ↓ (NEUTRAL)▲
Paid fines of ₹56,640 per exchange on May 25, 2026, and has been compliant since Feb 18, 2026; the low materiality (3/10) and swift remediation suggest minimal investor impact
- Novelix Pharmaceuticals ↓ (BULLISH)▲
Promoter holding diluted from 36.77% to 36.42% post-warrant conversion of 9,50,000 shares on May 29, 2026; no insider selling detected, indicating promoter confidence
- Coal India ↓ (NEUTRAL)▲
Fine of ₹5,45,160 for non-compliance with 4 regulations (17(1), 18(1), 19(1), 19(2)); the company has requested a waiver citing 'factors beyond control' and past favorable decisions, which may signal a low probability of actual penalty payment
- Reliable Data Services ↓ (NEUTRAL)▲
Fine of ₹47,200 for 8-day delay in independent director appointment; compliance achieved on Feb 14, 2026, with board noting 'not wilful' delay, suggesting a one-off governance lapse
- Coal India ↓ (BEARISH)▲
Non-compliance attributed to Ministry of Coal delays in appointing independent directors; this structural issue in PSUs could lead to recurring fines if not resolved, creating a governance overhang
- Reliable Data Services ↓ (BULLISH)▲
Board deferred independent director appointment on Nov 14, 2025, due to due diligence concerns, indicating proactive governance despite the lapse; this may be viewed positively by governance-focused investors
- Medico Remedies ↓ (NEUTRAL)▲
Disclosure delay was 'inadvertent' with no material financial impact; the company promises future compliance, reducing repeat risk
- Novelix Pharmaceuticals ↓ (BULLISH)▲
Warrant conversion by promoter entities (Srinidhi Fine-Chemicals LLP and Narahari Belide) shows continued promoter commitment, with no pledge or sale activity detected
Risk Flags (8)
- Coal India/Governance Risk↓ [HIGH RISK]▼
Non-compliance with 4 SEBI LODR regulations for the quarter ended March 31, 2026, including board composition and audit committee requirements; as a PSU, this could trigger MCA scrutiny and reputational damage
- Reliable Data Services/Governance Risk↓ [MEDIUM RISK]▼
8-day delay in independent director appointment for Q4 FY2025, despite board awareness at Nov 14, 2025 meeting; this pattern of delayed compliance raises questions about board oversight
- Medico Remedies/Compliance Risk↓ [LOW RISK]▼
Non-compliance with Regulation 6(1) for 48 days (Jan 1 to Feb 17, 2026); while resolved, the inadvertent disclosure delay suggests weak internal controls
- Coal India/Regulatory Risk↓ [MEDIUM RISK]▼
Waiver request may be denied if MCA takes a stricter stance on PSU governance, leading to actual penalty payment and potential follow-up actions
- Reliable Data Services/Repeat Offense Risk↓ [MEDIUM RISK]▼
The company previously deferred the independent director appointment, indicating a pattern of governance procrastination that could attract stricter MCA enforcement
- Coal India/Structural Risk↓ [HIGH RISK]▼
Dependence on Ministry of Coal for board appointments creates a systemic governance bottleneck, making compliance with SEBI LODR regulations challenging for PSUs
- Novelix Pharmaceuticals/Dilution Risk↓ [LOW RISK]▼
Promoter holding diluted by 35 bps post-warrant conversion; while not material, further conversions could erode minority shareholder value
- Medico Remedies/Disclosure Risk↓ [LOW RISK]▼
The inadvertent delay in disclosure suggests potential gaps in compliance monitoring systems, which could lead to future regulatory actions
Opportunities (8)
- Coal India/Waiver Precedent↓ (OPPORTUNITY)◆
Past waiver requests were favorably considered by exchanges; if granted, this would remove the fine overhang and signal regulatory leniency for PSUs, potentially boosting investor sentiment
- Reliable Data Services/Governance Improvement↓ (OPPORTUNITY)◆
Appointment of Mrs. Bhoomika Aditya Gupta as independent director on Feb 14, 2026, strengthens board composition; the company's due diligence focus suggests improved governance going forward
- Novelix Pharmaceuticals/Promoter Commitment↓ (OPPORTUNITY)◆
Conversion of 9,50,000 warrants by promoter entities at a time of market uncertainty signals strong insider conviction, which could attract value investors
- Medico Remedies/Compliance Resolution↓ (OPPORTUNITY)◆
Swift payment of fines and return to compliance since Feb 18, 2026, removes regulatory overhang; the low materiality (3/10) suggests no lasting impact on operations
- Coal India/PSU Governance Reform Catalyst↓ (OPPORTUNITY)◆
The fine could accelerate Ministry of Coal's appointment of independent directors, resolving the structural issue and improving CIL's governance profile
- Reliable Data Services/Board Meeting Insights↓ (OPPORTUNITY)◆
The May 30, 2026 board meeting discussed the fine and waiver application, indicating active management of the issue; watch for waiver approval as a positive catalyst
- Coal India/Regulatory Arbitrage↓ (OPPORTUNITY)◆
If the waiver is denied, the ₹5,45,160 fine is immaterial for a company of CIL's size (market cap >₹2 lakh crore), creating a buying opportunity on any temporary price dip
- Novelix Pharmaceuticals/No Insider Selling↓ (OPPORTUNITY)◆
Absence of promoter selling post-warrant conversion suggests no immediate liquidity concerns, making the stock attractive for long-term holders
Sector Themes (5)
- Board Composition Compliance Crisis◆
3 out of 4 filings (75%) involve non-compliance with SEBI LODR board composition regulations (Regulations 17, 18, 19), highlighting a systemic weakness in Indian corporate governance that may trigger stricter MCA enforcement
- PSU Governance Bottleneck◆
Coal India's non-compliance, attributed to Ministry of Coal delays, reveals a structural flaw in PSU governance where board appointments are controlled by government ministries, creating a compliance risk unique to state-owned enterprises
- Small-Cap Governance Lapses◆
Medico Remedies and Reliable Data Services, both smaller companies, show governance lapses (48-day and 8-day delays), suggesting that resource constraints in smaller firms lead to compliance failures, a trend that may attract MCA scrutiny
- Waiver Culture in Compliance◆
Both Coal India and Reliable Data Services have requested waivers of penalties, indicating a pattern where companies view fines as negotiable rather than binding, which could undermine SEBI's enforcement credibility
- Low Materiality of Fines◆
Fines range from ₹47,200 to ₹5,45,160, which are immaterial for most listed companies (0.001-0.01% of market cap), suggesting that current penalty levels may be insufficient to deter non-compliance, potentially leading to higher fines in the future
Watch List (8)
-
Watch for NSE/BSE decision on penalty waiver; if denied, it could set a precedent for stricter enforcement against PSUs. No specific date available, but follow-up with Ministry of Coal is ongoing
-
Monitor outcome of waiver application submitted post-May 30, 2026 board meeting; approval would remove governance overhang, while denial could lead to reputational damage
-
Track any further regulatory filings from Medico Remedies for repeat offenses; the company's promise of future compliance needs validation in upcoming quarterly reports
-
Monitor remaining 21,00,000 warrants held by Srinidhi Fine-Chemicals LLP; further conversions could dilute promoter holding further and impact stock price
-
Watch for announcements from Ministry of Coal on appointment of independent directors; resolution of this issue would be a positive catalyst for CIL's governance score
-
Ensure compliance with Regulation 17(1) for the quarter ending June 30, 2026; any repeat lapse would escalate risk and attract stricter MCA action
-
Monitor CIL's next quarterly compliance filing for the quarter ending June 30, 2026, to see if board composition issues are resolved; failure to comply could lead to higher penalties
- MCA Enforcement Actions👁
Watch for any MCA-initiated prosecutions or show-cause notices following these SEBI fines, particularly for Coal India, as the regulator may escalate enforcement for repeat or systemic non-compliance
Filing Analyses
(4)
03-06-2026
Medico Remedies Limited received a Show Cause Notice (SoP) from NSE and BSE on May 20, 2026, for alleged non-compliance with Regulation 6(1) of SEBI LODR Regulations for the period January 1 to February 17, 2026. The company paid fines of ₹56,640 (inclusive of GST) to each exchange on May 25, 2026, and has been compliant since February 18, 2026. The disclosure was delayed inadvertently, but no material financial or operational impact is expected.
- · Non-compliance period: January 1, 2026 to February 17, 2026
- · Company has been compliant with Regulation 6(1) since February 18, 2026
- · Disclosure delay was inadvertent; company promises future compliance
03-06-2026
Novelix Pharmaceuticals Limited received disclosures under SEBI Takeover Regulations regarding the allotment of 9,50,000 equity shares on May 29, 2026, to promoter and promoter group entities upon conversion of warrants issued via preferential allotment. The allottees are Srinidhi Fine-Chemicals LLP (8,00,000 shares) and Narahari Belide (1,50,000 shares). Post-allotment, the promoter/promoter group holding in terms of shares carrying voting rights decreased slightly from 36.77% to 36.42% on a diluted basis, while the total diluted share capital increased.
- · The warrants were originally issued through preferential allotment and converted on May 29, 2026.
- · Srinidhi Fine-Chemicals LLP held 29,00,000 warrants before conversion and 21,00,000 warrants after conversion.
- · Narahari Belide held 5,50,000 warrants before conversion and 5,50,000 warrants after conversion (no change).
- · The promoter/promoter group holding (diluted) decreased marginally from 41.08% to 41.08% (no change on a fully diluted basis including warrants).
- · The company was formerly known as Trimurthi Limited.
03-06-2026
Coal India Limited (CIL) received a notice from the National Stock Exchange (NSE) imposing a fine of ₹5,45,160 (inclusive of GST) for non-compliance with SEBI LODR Regulations 2017 (Regulations 17(1), 18(1), 19(1) & 19(2)) for the quarter ended March 31, 2026. The company attributes the non-compliance to factors beyond its control, as board appointments are made by the President of India, and has requested a waiver of the penalty.
- · The fine is for non-compliance with Regulations 17(1), 18(1), 19(1) & 19(2) of SEBI LODR, 2015, which relate to board composition, independent directors, and audit committee requirements.
- · CIL states the non-compliance was not due to its negligence and that it has been following up with the Ministry of Coal for appointment of requisite independent directors.
- · The company has requested a waiver of the penalty, noting that similar waiver requests were favorably considered by exchanges in the past.
- · The order/notice from NSE was received on June 2, 2026.
03-06-2026
Reliable Data Services Limited was fined ₹47,200 (inclusive of 18% GST) by NSE and BSE for non-compliance with Regulation 17(1) of the SEBI Listing Regulations regarding Board composition for the quarter ended December 31, 2025. The Board, at its meeting on May 30, 2026, noted the delay was not wilful but due to due diligence issues in appointing an Independent Director, and confirmed that compliance was achieved on February 14, 2026 with the appointment of Mrs. Bhoomika Aditya Gupta. The company has paid the fine and submitted a waiver application, but the incident highlights a governance lapse that required regulatory intervention.
- · The non-compliance was for the quarter ended December 31, 2025, with 8 days of delay.
- · The Board meeting that discussed the fine was held on May 30, 2026.
- · The company had previously deferred the appointment of an Independent Director at its November 14, 2025 board meeting due to due diligence concerns.
- · Compliance was achieved on February 14, 2026, with the appointment of Mrs. Bhoomika Aditya Gupta.
- · The company has paid the fine and submitted a waiver application to both NSE and BSE.
- · Failure to pay the fine within 15 days of the notice (February 27, 2026) could lead to freezing of promoter shareholding and transfer to Z category (trade-for-trade basis).
- · The fine was levied under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.
- · The company's ISIN is INE375Y01018, NSE Symbol RELIABLE, BSE Scrip Code 544207.
Get daily alerts with 8 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 4 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India MCA Corporate Compliance Enforcement
🇮🇳 More from India
View all →June 03, 2026
India Pre-Market Regulatory Roundup — June 03, 2026
India Pre-Market Regulatory Roundup
June 03, 2026
India Upcoming Corporate Actions BSE NSE — June 03, 2026
India Upcoming Corporate Actions BSE NSE
June 03, 2026
India Merger Acquisition MCA Regulatory Filings — June 03, 2026
India Merger Acquisition MCA Regulatory Filings
June 03, 2026
BSE Realty Real Estate Sector Regulatory Filings — June 03, 2026
BSE Realty Real Estate Sector Regulatory Filings